Kairos Pharma Ltd. to Showcase Innovations at H.C. Wainwright Global Investment Conference

Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company dedicated to developing innovative cancer therapeutics, is set to participate in the H.C. Wainwright 27th Annual Global Investment Conference. The event, taking place from September 8 to 10, 2025, at the Lotte New York Palace Hotel in New York City, will feature Kairos Pharma in one-on-one meetings and a virtual presentation accessible through their website, https://kairospharma.com.

The company's presentation will focus on its lead candidate, ENV105, an antibody designed to target CD105, a protein implicated in resistance to various cancer treatments. By addressing this resistance mechanism, ENV105 aims to enhance the efficacy of standard therapies across multiple cancer types, including castrate-resistant prostate cancer and lung cancer, where it is currently undergoing Phase 2 and Phase 1 clinical trials, respectively.

This participation underscores Kairos Pharma's commitment to advancing oncology therapeutics and its potential to make significant strides in overcoming drug resistance and immune suppression in cancer. The conference offers a platform for the company to engage with investors and the broader investment community, showcasing its innovative approach to tackling some of the most challenging aspects of cancer treatment.

For those interested in learning more about Kairos Pharma and its groundbreaking work in cancer therapeutics, additional information is available on the company's website, https://www.KairosPharma.com, and through the latest news and updates in the company's newsroom at https://ibn.fm/KAPA.